
==== Front
Neurooncol Adv
Neurooncol Adv
noa
Neuro-Oncology Advances
2632-2498
Oxford University Press US

10.1093/noajnl/vdae090.128
vdae090.128
Final Category: Surgical Advances and Device Advances
AcademicSubjects/MED00300
AcademicSubjects/MED00310
SRGD-03 PRESENTATION AND POST-OPERATIVE OUTCOMES IN DIVERSE PATIENTS RECEIVING LASER ABLATION FOR CENTRAL NERVOUS SYSTEM METASTASES
Haskell-Mendoza Aden Duke University School of Medicine, Durham, NC, USA

Gonzalez Ariel Duke University School of Medicine, Durham, NC, USA

Reason Ellery Duke University School of Medicine, Durham, NC, USA

Jackson Joshua Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA

Seas Andreas Duke University School of Medicine, Durham, NC, USA
Department of Biomedical Engineering, Duke University Pratt School of Engineering, Durham, NC, USA

Zaidi Saif Preston Robert Tisch Brain Tumor Center, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA

Mohan Aditya Preston Robert Tisch Brain Tumor Center, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA

Lerner Emily Preston Robert Tisch Brain Tumor Center, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA

Srinivasan Ethan Department of Neurosurgery, Johns Hopkins University, Baltimore, MD, USA

Bradbury Claire Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA

Herndon James Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA

Goodwin C Rory Duke Center for Brain and Spine Metastasis, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA

Fecci Peter Preston Robert Tisch Brain Tumor Center, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA
Duke Center for Brain and Spine Metastasis, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA

8 2024
02 8 2024
02 8 2024
6 Suppl 1 2024 SNO/ASCO CNS Metastases Conference i39i39
© The Author(s) 2024. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Abstract

OBJECTIVE

Laser interstitial thermal therapy (LITT) is a minimally invasive option for the management of intracranial pathologies, including radiographically progressive tumors following stereotactic radiosurgery. Although LITT has been increasingly accepted in recent years, little is known regarding presentation and outcomes of patients with diverse backgrounds, particularly for centers specializing in central nervous system (CNS) metastases.

METHODS

All patients receiving their index LITT for brain metastasis at a single center from 2015 – 2023 were retrospectively reviewed. Patient demographics and geospatial data was used to compare differences in receipt of LITT by race/ethnicity, survival outcomes, and clinical trial enrollment.

RESULTS

From 2015-2023, 137 patients presented for LITT to 146 intracranial lesions. One hundred and six patients (77.3%) were non-Hispanic White (NHW), 25 (18.2%) were Black or African American, 5 (3.6%) were Asian American/Pacific Islander, and 1 (0.7%) was Hispanic or Latino (Hispanic or non-White, HNW). Among HNW patients, women more frequently received LITT (P = 0.022), with skin cancers being a more frequent indication among NHW patients (P = 0.019). NHW patients traveled a median of 62.0 (6.2 – 1045.9) miles to receive LITT vs 25.9 (1.31 – 238.3) miles for HNW patients (p = 0.001). In multivariate analyses, post-LITT overall survival was predicted by pre-LITT KPS (P = 0.0007) and recurrent tumor on biopsy (P = 0.0002), while probability of clinical trial enrollment was lower among those of female sex (P = 0.049), HNW race/ethnicity (P = 0.041), or external referral status (P = 0.035).

CONCLUSION

Patient sex, systemic disease histology, and distance from a treating center may differentially influence presentation for LITT according to underlying racial/ethnic identity. However, patients successfully treated in multidisciplinary CNS metastasis centers experience excellent post-procedural outcomes. Such centers should enact measures to ensure equitable clinical trial enrollment.
==== Body
pmc
